DEA Extends Telemedicine Buprenorphine Rules Through 2026
A final rule now permanently allows buprenorphine via telehealth for up to 6 months without an in-person visit.
Body: [News-style article: what the rule changes, what the 6-month window means in practice, why the field had been bracing for a cliff, what clinicians and patients should know, caveats on state-by-state variation, how it affects telehealth-first programs like Bicycle Health and Ophelia. 800 words.]
Sources Cited
- 01.A
Filed Under
DEAMAT — BuprenorphineFederalPolicy
Keep up with the reporting.
One email each morning with the stories that put days like this in context.
Continue reading
More from this section
The Overdose Numbers Are Falling. Cocaine Is the Exception Nobody's Toasting.
CDC data show overdose deaths falling nationally, but stimulant-only deaths are rising, and Medicaid coverage for the one treatment that works, contingency management, remains rare.
Policy & FundingSAMHSA Killed Funding for Fentanyl Test Strips. Then CDC Bragged About Falling Overdose Deaths.
SAMHSA cut federal funding for fentanyl test strips and syringes in April. Five months later, CDC's new overdose dashboard shows deaths falling 12.3% — and harm reduction groups in Kentucky, Ohio, and South Carolina are the ones absorbing the contradiction.
Policy & FundingDEA Drew a Real Line on Kratom. Whether It Holds Isn't Decided Yet.
The federal comment period on DEA's proposed 0.05% threshold for 7-hydroxymitragynine closed September 10, 2026. Here's the real state of kratom scheduling right now — and what it doesn't change.